Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series
Repository Usage Stats
<jats:p>Treatment options for drug-resistant CMV are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically-confirmed resistance to letermovir while on therapy.</jats:p>
Published Version (Please cite this version)10.1128/aac.02337-18
Publication InfoTurner, Nicholas; Strand, Andrew; Grewal, Dilraj S; Cox, Gary; Arif, Sana; Baker, Arthur W; ... Wolfe, Cameron R (n.d.). Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series. Antimicrobial Agents and Chemotherapy. 10.1128/aac.02337-18. Retrieved from https://hdl.handle.net/10161/17912.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.